GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
tovecimig 
GtoPdb Ligand ID: 14507
|
Synonyms: ABL001 | CTX-009 | CTX009
Compound class:
Antibody
Comment: Tovecimig (CTX-009; formerly ABL001) is a bispecific monoclonal antibody that simultaneously blocks the signalling pathways that are activated by the delta-like ligand-4 (DLL4; Notch signaling) and vascular endothelial growth factor A (VEGF-A) [4]. The VEGF-A binding heavy chains of tovecimig are derived from the established anti-VEGF-A biologic bevacizumab. Two single chain variable fragments (scFv) that bind to human DLL4 are linked to the C-termini of the anti-VEGF-A heavy chains [1].
|
| Selectivity at ligand targets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License